Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), (Catalyst Pharmaceuticals), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today reported financial results for the first quarter ended March 31, 2015.

“This quarter we have been working to advance regulatory and commercial affairs and are moving closer to initiating the submission of our rolling NDA to the FDA next quarter for Firdapse® for the symptomatic treatment of LEMS,” said Patrick J. McEnany, Catalyst’s Chief Executive Officer. “This past quarter we made important strides on our commercial infrastructure, significant progress with our pipeline, and also strengthened our cash position.”

Read the full text here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=912411

Leave a comment

Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), (Catalyst Pharmaceuticals), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that it will release First Quarter financial results after market close on Monday, May 11, 2015. Catalyst management will host an investment-community conference call at 8:30 a.m. EDT on Tuesday, May 12, 2015 to discuss the financial results and provide a corporate update.

Read the full text here: http://ir.catalystpharma.com/releasedetail.cfm?releaseid=910607

Leave a comment

Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), (Catalyst Pharmaceuticals), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that Shin Oh, MD, one of its clinical investigators, will be making an oral presentation of safety and efficacy data from the Firdapse® Phase 3 clinical trial in patients with Lambert-Eaton myasthenic syndrome (LEMS) at the American Academy of Neurology (AAN) 67th Annual Meeting. The AAN meeting will be held April 18 to 25, 2015, in Washington, DC.

Read the full text here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=906410

 

Leave a comment

Catalyst Pharmaceutical Partners, Inc. (Catalyst Pharmaceuticals) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today reported financial results for the fourth quarter and year-ended December 31, 2014.

“2014 was a year of great progress for Catalyst, clearly highlighted by the positive results from our pivotal Phase 3 Firdapse™ trial in LEMS,” said Patrick J. McEnany, Chief Executive Officer of Catalyst. “As we look towards the NDA submission for Firdapse™ this year, we continue to build our commercial infrastructure, along with looking for Firdapse™ expansion opportunities to help patients beyond the LEMS indication. We continue to advance the development of our pipeline with results from the CPP-115 Phase 1 trial and the Tourette disorder open label study expected in the second quarter of 2015.”

Read the full text here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=901709

Leave a comment

Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), (Catalyst Pharmaceuticals), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that the Company will be presenting at the 27th Annual ROTH Conference, in California. Patrick J. McEnany, Catalyst’s Chief Executive Officer and Steven Miller, Ph.D., Chief Scientific Officer/COO, will provide an overview of the Company and its key programs on Tuesday, March 10 th at10:30 am PT / 1:30 pm ET. The Company’s presentation materials will be available on the “Investors” section of the Company’s website,www.catalystpharma.com following the presentation.

Read the full text here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=900494

Leave a comment

Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), (Catalyst Pharmaceuticals), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for Firdapse™ for treatment of patients with Congenital Myasthenic Syndromes (CMS).

Read the full text here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=900213

Leave a comment

CORAL GABLES, Fla., Feb. 19, 2015 (GLOBE NEWSWIRE) — Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), (Catalyst Pharmaceuticals), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced the appointment of Richard J. Daly and Donald A. Denkhaus to the Company’s Board of Directors.

“Catalyst is pleased to welcome such exceptional and successful pharmaceutical business leaders to its board, adding additional financial, operational and commercial expertise as we transform from a clinical stage company to a commercial operation,” said Patrick J. McEnany, Chairman and CEO of Catalyst.

Read the full text here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=897261

Leave a comment

CORAL GABLES, Fla., Feb. 9, 2015 (GLOBE NEWSWIRE) — Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) (Catalyst Pharmaceuticals) today reported that it has closed its previously announced public offering of shares of its common stock. The Company sold 11,500,000 shares of its common stock in the offering, which includes 1,500,000 shares that were issued upon the full exercise by the underwriters of their over-allotment option. The offering price was $3.25 per share, and the net proceeds from the sale of the shares is expected to be approximately $34.7 million. Piper Jaffray & Co. acted as the sole lead book-running manager and SunTrust Robinson Humphrey acted as the passive book-running manager with respect to this offering. Further, Roth Capital Partners and H.C. Wainwright & Co. acted as the lead co-manager and co-manager, respectively.

Read the full text here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=895404

Leave a comment

Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) (Catalyst Pharmaceuticals) announced the pricing of its previously announced underwritten public offering of 10,000,000 shares of its common stock at an offering price of $3.25 per share. In connection with the offering, Catalyst has also granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock to cover over-allotments, if any.

Read the full text here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=894640

Leave a comment

Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) announced today that it intends to offer shares of its common stock in a public offering. Catalyst also expects to grant the underwriters a 30-day option to purchase additional shares of its common stock to cover over-allotments, if any. Catalyst plans to use the net proceeds from the offering (i) to pay milestone payments due on final approval of an NDA for Firdapse™; (ii) to pay pre-commercialization and other expenses required to launch Firdapse™; (iii) to fund future clinical studies of Firdapse™ for other indications, to the extent that such additional studies are required; (iv) to fund future clinical and nonclinical studies of CPP-115; and (v) for general corporate purposes.

Read the full release here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=894494

Leave a comment
Follow

Get every new post delivered to your Inbox.

Join 239 other followers

%d bloggers like this: